← Back to Clinical Trials
Recruiting NCT04296487

NCT04296487 Introduction of ACI for Cartilage Repair

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04296487
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire Vaudois
Condition Articular Cartilage Defect
Study Type INTERVENTIONAL
Enrollment 218 participants
Start Date 2017-09-01
Primary Completion 2030-09

Eligibility & Interventions

Sex All sexes
Min Age 15 Years
Max Age 50 Years
Study Type INTERVENTIONAL
Interventions
autologous chondrocytes

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 218 participants in total. It began in 2017-09-01 with a primary completion date of 2030-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study was aimed to evaluate effectiveness and safety of autologous chondrocyte suspension for treatment of knee articular cartilage defects.

Eligibility Criteria

Inclusion Criteria: 1. Age between 15 and 50. 2. Lesions classified as ICRS Grade III or IV and smaller than 15 cm2 3. Lesions that have failed prior therapy (conservative or surgical treatment ≥ six months) 4. Subjects who understand and sign the consent form for this study Exclusion Criteria: 1. Body mass index (BMI) of 35 or more 2. Osteoarthritis or rheumatoid arthritis 3. Diffuse lesion 4. Uncorrected mal-alignment, ligamentous instability, or meniscal tear 5. Presence of growth cartilage (15-18 years old) 6. Active smoking or drug consumption 7. Women who are pregnant 8. Positive serology for HIV-1 or HIV-2, Hepatitis B and C and syphilis 9. Proven allergy to porcine collagen, penicillin and gentamicin 10. Poor compliance

Contact & Investigator

Central Contact

Robin MARTIN, MD

✉ robin.martin@chuv.ch

📞 021 314 76 79

Principal Investigator

Robin MARTIN, MD

PRINCIPAL INVESTIGATOR

CHUV

Frequently Asked Questions

Who can join the NCT04296487 clinical trial?

This trial is open to participants of all sexes, aged 15 Years or older, up to 50 Years, studying Articular Cartilage Defect. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04296487 currently recruiting?

Yes, NCT04296487 is actively recruiting participants. Contact the research team at robin.martin@chuv.ch for enrollment information.

Where is the NCT04296487 trial being conducted?

This trial is being conducted at Lausanne, Switzerland.

Who is sponsoring the NCT04296487 clinical trial?

NCT04296487 is sponsored by Centre Hospitalier Universitaire Vaudois. The principal investigator is Robin MARTIN, MD at CHUV. The trial plans to enroll 218 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology